On August 27, 2025 Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, reported that CFO Raphi Levy will present and meet investors in the following five investor conferences in September 2025 (Press release, Alpha Tau Medical, AUG 27, 2025, View Source [SID1234655506]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Alpha DaRT platform is a novel approach using localized alpha particle radiotherapy with the goal of destroying solid tumors while sparing surrounding healthy tissue. With broad potential applicability for local tumor control, together with signs of compelling immuno-stimulatory activity, the platform technology is being explored for utilization alone or synergistically with other cancer treatment modalities. Key milestones and pivotal data from multiple clinical trials in different indications are expected in 2025 and 2026.

Event: Citi 2025 Biopharma Back to School Summit
Format: 1×1 Meetings
Date: September 2-3, 2025
Location: Boston, MA

Event: H.C. Wainwright 27th Annual Global Investment Conference
Format: Company Presentation and 1×1 Meetings
Date: September 9, 2025
Time 3:00 – 3:30pm
Location: New York, NY

Event: Oppenheimer’s Third Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
Format: 1×1 Meetings
Date: September 11, 2025
Location: New York, NY

Event: RTH & Co / Redburn Atlantic – Radiopharma Landscape Conference
Format: 1×1 Meetings
Date: September 26, 2025
Location: New York, NY

Event: Lytham Partners Fall 2025 Investor Conference
Format: 1×1 Meetings
Date: September 30, 2025
Location: Virtual

Mr. Levy will be available for 1×1 investor meetings at all conferences. Please reach out to your representatives at the respective conference organizers to schedule.

About Alpha DaRT

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

On August 27, 2025 Wugen, Inc., a clinical-stage biotechnology company pioneering the next generation of allogeneic, off-the-shelf CAR-T cell therapies, reported the closing of $115 million equity financing led by Fidelity Management & Research Company, with participation from RiverVest Venture Partners, Lightchain Capital, Abingworth, ICG, LYZZ Capital, Tybourne Capital Management, Aisling Capital Management, and other leading life sciences investors (Press release, Wugen, AUG 27, 2025, View Source [SID1234655521]). The proceeds will advance the ongoing pivotal T-RRex study of WU-CART-007 in relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T‑LBL).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

WU-CART-007, also known as soficabtagene geleucel, is a CD7-targeted, CRISPR-edited allogeneic CAR-T cell therapy with potential to be the first approved "off-the-shelf" CAR-T for T-cell malignancies. In a completed global Phase 1/2 study, WU-CART-007 achieved an overall response rate (ORR) of 91% and a composite complete remission (CRc) rate of 73% at the recommended Phase 2 dose. The median duration of response exceeded six months with manageable safety. These data, presented at the 2024 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting & Exposition, substantially surpass the outcomes achieved with current standard-of-care therapies.

"This financing comes at a decisive time for Wugen as we advance WU-CART-007 through our ongoing pivotal study with a clear path to a BLA filing in 2027," said Kumar Srinivasan, Ph.D., MBA, president, and chief executive officer of Wugen. "Relapsed and refractory T-ALL/T-LBL are aggressive malignancies resistant to current treatment options. We are committed to delivering an accessible, off-the-shelf therapy that can significantly improve the trajectory of patients’ care. We are grateful for the support of a world-class syndicate of investors who share our vision of transforming the treatment landscape for T‑cell malignancies."

"WU-CART-007’s robust response in a heavily pretreated patient population—coupled with manageable safety and scalable manufacturing—positions it as a potential first-in-class therapy," said Cherry Thomas, M.D., chief medical officer of Wugen. "Our pivotal T-RRex trial is designed to evaluate WU‑CART-007 in a single study for both pediatric and adult patients, with the goal of offering a potentially curative option where current salvage therapies fail."

"RiverVest has been impressed by the Wugen team’s efforts advancing WU-CART-007 into this pivotal study, and we are pleased that several of the world’s leading cancer centers are participating," said Niall O’Donnell, Ph.D., Managing Director at RiverVest. "We are optimistic about Wugen’s potential to transform care for patients who currently face poor outcomes and limited treatment options, and we look forward to supporting WU-CART-007’s continued progress."

Use of Proceeds and Next Steps
Proceeds from this financing will fund the advancement of the pivotal T-RRex trial in patients with relapsed/refractory or minimal residual disease-positive T-ALL/T-LBL, regulatory engagement with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), and preparations for commercial-scale manufacturing. The company anticipates a Biologics License Application (BLA) submission in 2027.

About WU-CART-007

WU-CART-007 is an allogeneic, off-the-shelf, CD7-targeted CAR-T cell therapy engineered to overcome the technological challenges of harnessing CAR-T cells to treat T-cell cancers. Wugen is deploying CRISPR/Cas9 gene editing technology to delete CD7 and the T cell receptor alpha constant (TRAC) genes, thereby preventing CAR-T cell fratricide and mitigating the risk of graft-versus-host disease (GvHD). WU‑CART-007 is manufactured using healthy donor-derived T cells to eliminate the risk of malignant cell contamination historically observed in the autologous CAR-T setting. WU-CART-007 is currently being evaluated in a global pivotal clinical trial for relapsed or refractory T-ALL/T-LBL. More information on the Phase 1/2 trial is available on clinicaltrials.gov, identifier NCT04984356 and on the pivotal trial on clinicaltrials.gov, identifier NCT06514794.

WU-CART-007 has received Regenerative Medicine Advanced Therapy (RMAT), Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the U.S. Food and Drug Administration and Priority Medicines (PRIME) Scheme designation in the European Union for the treatment of relapsed or refractory T-ALL/T-LBL. RMAT and PRIME designations provide increased agency support to expedite the development and review of promising therapies for patients in need.

On August 27, 2025 CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a clinical stage cancer immunotherapy company, reported the pricing of a best-efforts public offering of 1,111,200 shares of its common stock (Press release, Cel-Sci, AUG 27, 2025, View Source [SID1234655537]). Each share of common stock is being sold at a public offering price of $9.00 per share. Total gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, are expected to be approximately $10 million. The offering is expected to close on August 29, 2025, subject to satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company intends to use the net proceeds from the offering to fund the continued development of Multikine, general corporate purposes, and working capital.

ThinkEquity is acting as the sole placement agent for the offering.

The securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-288515), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 3, 2025, and declared effective on August 12, 2025. The offering will be made only by means of a written prospectus. A final prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the SEC on its website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering may also be obtained, when available, from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On August 27, 2025 Adcendo, a clinical-stage biotech company pioneering the development of first and best-in-class ADCs for cancers with a high unmet medical need, reported that management will participate in five upcoming investor conferences in September (Press release, ADCendo, AUG 27, 2025, View Source [SID1234655628]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi 2025 Biopharma Back-to-School Conference
Format: 1×1 meetings
Date: Tuesday, September 2, 2025
Location: Boston, MA

Wells Fargo 2025 Healthcare Conference
Format: Company presentation
Date: Wednesday, September 3, 2025
Time: 3:45 p.m. ET
Location: Boston, MA

Cantor Global Healthcare Conference
Format: 1×1 meetings
Date: Thursday, September 4, 2025
Location: New York, NY

Morgan Stanley 23rd Annual Global Healthcare Conference
Format: Company presentation
Date: Monday, September 8, 2025
Time: 1:50 p.m. ET
Location: New York, NY

Bank of America Healthcare Trailblazers Private Company Conference
Format: 1×1 meetings
Date: Wednesday, September 17, 2025
Location: Boston, MA

On August 27, 2025 AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, reported that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences (Press release, AnaptysBio, AUG 27, 2025, View Source [SID1234655507]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cantor Global Healthcare Conference 2025, New York, NY

Format – Fireside chat and one-on-one investor meetings
Date and Time – Wednesday, Sept. 3, 2025 at 8:00am ET / 5:00am PT
2025 Wells Fargo Healthcare Conference, Boston, MA

Format – Fireside chat and one-on-one investor meetings
Date and Time – Thursday, Sept. 4, 2025 at 11:00am ET / 8:00am PT
Stifel 2025 Virtual Immunology and Inflammation Forum, Virtual

Format – Fireside chat and one-on-one investor meetings
Date and Time – Tuesday, Sept. 16, 2025 at 12:00pm ET / 9:00am PT
Live webcasts of the fireside chats will be available on the investor section of the Anaptys website at View Source Replays of the webcasts will be available for at least 30 days following the events.